Protein Drug Delivery: Penetrating a Growth Market

Published by: Datamonitor

Published: Mar. 7, 2005 - 108 Pages

Table of Contents

CHAPTER 1 EXECUTIVE SUMMARY

Scope

Datamonitor's opinion on the current and future protein drug delivery market

CHAPTER 2 INTRODUCTION TO PROTEIN DRUG DELIVERY

Key Findings

Protein therapeutics

The protein therapeutic market size and therapy area exposure

Drug delivery of proteins

Drug delivery by therapy area

Reformulation of protein therapeutics

Drug formulation by therapy area

Drug formulation by drug delivery method

Drug formulation by drug launch year

Drug formulation by dosing frequency

Delivery devices for protein therapeutics

Use of devices by therapy area

Use of devices by drug delivery method

Use of devices by drug formulation

Use of devices by drug launch year

CHAPTER 3 DYNAMICS OF PROTEIN DRUG DELIVERY MARKET

Key findings

Development of protein drug delivery market

Changing dynamics of drug delivery market

Protein drug delivery technologies are primarily developed by specialists

Strategic issues for protein drug delivery companies

Drivers to the protein drug delivery market

Growth of biotechnology and protein products creates significant market potential

Implications and recommendations

Limitations to protein reformulation and drug delivery technologies

Cost of investment

Limits to technology application

Delivery profile of protein therapeutics

Barriers to entry for new companies/technologies

Implications and recommendations

Key factors defining winners and losers

Strategic issues for pharmaceutical companies using protein drug delivery technologies

General strategic objectives of drug reformulation and the application of drug delivery technologies

Aims for the use of protein drug delivery technologies

Maintain market presence

Gaining competitive edge and differentiation

Expand therapeutic use

Concerns for pharmaceutical companies when implementing product drug delivery technologies

Pricing and royalties

Implications and recommendations

Key factors defining winners and losers

CHAPTER 4 APPENDIX

Datamonitor's in-house proprietary protein database

List of Tables

Table 1: The protein therapeutic market is estimated to grow by 10.5% between 2003 and 2010

Table 2: Non-injectable drug delivery routes are expected to show the greatest growth in the protein therapeutic market, however, this growth is from small starting sales

Table 3: Sustained release formulations are expected to report greater growth as a percentage, but the actual increase of immediate release formulations will be greater

Table 4: Protein therapeutics with the availability of a device are expected to show greater growth than that of products without a device available

List of Figures

Figure 1: Oncology is the largest therapy area of the protein therapeutic market by sales

Figure 2: Oncology is the largest therapy area of the protein therapeutic market by sales

Figure 3: Survey respondents recognized oncology, AIID and diabetes and endocrinology as the key protein therapeutic markets

Figure 4: Subcutaneous injection is the primary route of protein therapeutics delivery

Figure 5: Subcutaneous injection will remain the primary route of protein delivery, but its share of the market will decrease

Figure 6: AIID is expected to show high growth in protein therapeutic sales between 2003 and 2010

Figure 7: Most protein therapeutics are immediate release formulations

Figure 8: There are four key therapy areas with sustained release protein therapeutics

Figure 9: The majority of sustained release formulations are delivered by subcutaneous injection

Figure 10: In 2010, most of the sales from sustained release products will come from products launched in the late 1990's and early 2000's

Figure 11: Convenient but regular dosing regimes appear to be the primary market for sustained release technologies

Figure 12: The proportion of sales originating from sustained release products is expected to increase in certain dosing categories, including once a day

Figure 13: Some therapy areas are associated with key dosing regimens

Figure 14: Most protein therapeutic sales relate to products without devices available

Figure 15: Protein therapeutics in most therapy areas use devices

Figure 16: Most devices are used with protein therapeutics administered by subcutaneous delivery

Figure 17: A higher proportion of sustained release protein therapeutics have devices available

Figure 18: In 2010, most of the sales from protein therapeutics with a device available will have launched over recent years

Figure 19: The protein drug delivery market is driven by specialist companies developing technologies for use by pharmaceutical companies

Figure 20: There are different factors which can be considered inhibitors to the use of protein drug delivery technologies

Figure 21: Four classes of strategic objectives for drug reformulation

Figure 22: Several factors are considered key drivers to the protein drug delivery market

Figure 23: Prescription volumes of Intron, PEG-Intron and Pegasys in the US, 1999-2003: PEG-Intron saw a rapid uptake following its launch, cannibalising Intron's prescription volumes, but prescription volumes have declined heavily since the launch of Pegasys

Figure 24: Prescription volumes of Intron, PEG-Intron and Pegasys in Europe, 1999-2003; PEG-Intron heavily cannibalized Intron's prescription volume following its launch

Figure 25: Sales of Intron, PEG-Intron and Pegasys in the US, 1999-2003: Intron's sales have been static, while PEG-Intron's sales grew rapidly following its launch, but has been declining heavily since 2003

Figure 26: Sales of Intron, PEG-Intron and Pegasys in Europe, 1999-2003: PEG-Intron's sales are greater than Intron

Figure 27: Price of Intron, PEG-Intron and Pegasys per week in the US, 1999-2003: Pegasys is more expensive than PEG-Intron

Figure 28: Price of Intron, PEG-Intron and Pegasys per week in Europe, 1999-2003: While PEG-Intron and Pegasys have had similar price points, Intron price has been far higher since 2002

Figure 29: Prescription volumes of Remicade, Enbrel and Humira in the US, 1999-2003: Enbrel has dominated the rheumatoid arthritis over the last five years

Figure 30: Standardized volumes by patient number for Remicade, Enbrel and Humira in the US, 1999-2003: Remicade's less frequent

Figure 31: Sales of Remicade, Enbrel and Humira in the US, 1999-2003: Remicade and Enbrel have achieved similar levels of sales

Figure 32: Price of Remicade, Enbrel and Humira per week in the US, 1999-2003: Humira is the most expensive treatment

Figure 33: Prescription volumes of Humalog, Humulin and NovoLog/NovoRapid in the US, 1999-2003: switching from human insulin to insulin analogues

Figure 34: Prescription volumes of Humalog, Humulin and NovoLog/NovoRapid in the US, 1999-2003: insulin analogues dominate the market

Figure 35: Sales of Humalog, Humulin and NovoLog/NovoRapid in the US, 1999-2003: Humulin's sales decline as patient's switch to insulin analogues

Figure 36: Sales of Humalog, Humulin and NovoLog/NovoRapid in Europe, 1999-2003: Humalog has the highest sales

Figure 37: Price of Humalog, Humulin and NovoLog/NovoRapid per unit in the US, 1999-2003: Humulog's price has quadrupled over the last five years

Figure 38: Price of Humalog, Humulin and NovoLog/NovoRapid per unit in Europe, 1999-2003; since 2001, the drugs have a similar price point

Figure 39: Prescription volumes of Avonex, Betaseron and Rebif in the US, 1999-2003: Betaseron has dominated the market since 2000

Figure 40: Prescription volumes of Avonex, Betaseron and Rebif in Europe, 1999-2003: Betaseron has been the market leader over the last five years

Figure 41: Sales of Avonex, Betaseron and Rebif in the US, 1999-2003: Avonex has had higher sales than Betaseron and Rebif

Figure 42: Sales of Avonex, Betaseron and Rebif in Europe, 1999-2003: the drugs have seen similar level of sales since 2001

Figure 43: Price of Avonex, Betaseron and Rebif per week in the US, 1999-2003; Rebif has been the most expensive treatment

Figure 44: Price of Avonex, Betaseron and Rebif per week in Europe, 1999-2003; Rebif remains the most expensive treatment

Figure 45: Marketing product mix of Sanofi Aventis's diabetes and endocrinology franchise

Figure 46: Prescription volumes of Neupogen and Neulasta in the US, 1999-2003: Neupogen sales have fallen since the launch of Neulasta in 2002

Figure 47: Sales of Neupogen and Neulasta in the US, 1999-2003: Neulasta's sales were greater than Neupogen a year after its launch

Figure 48: Price of Neupogen and Neulasta per day in the US, 1999-2003: the drugs have a similar price point on a daily basis

Figure 49: Prescription volumes of Epogen, Procrit and Aranesp in the US, 1999-2003: Epogen prescription volume has continued to grow after the launch of its follow-on product Aranesp

Figure 50: Prescription volumes of Eprex versus Aranesp in Europe, 1999-2003: the prescription volume of Eprex has declined following the launch of Aranesp

Figure 51: Sales of Epogen, Procrit and Aranesp in the US, 1999-2003: Sales of Amgen's Epogen has continued to grow at a similar rate despite the launch of its follow-up product Aranesp

Figure 52: Sales of Eprex versus Aranesp in Europe, 1999-2003: sales of Eprex have grown steadily, despite the launch of Aranesp

Figure 53: Price of Epogen, Procrit and Aranesp per unit in the US,1999-2003: Aranesp entered the market at a higher price than its predecessor Epogen and by 2003, the price had more doubled

Figure 54: Price of Eprex and Aranesp per unit in Europe, 1999-2003: since Aranesp's launch at a higher price point, Eprex unit price has been steadily increasing

Abstract

• Analysis of the protein therapeutics portfolio and pipeline for 50 leading pharma and biotech companies
• Benchmarking of the current and future protein drug delivery market by technology and therapeutic focus
• Evaluation of the key drivers and resistors of the protein drug delivery market
• Assessment of the strategic aims of pharmaceutical companies in utilizing protein drug delivery technologies

• Identify the opportunities provided by current and future protein drug delivery technologies to effectively plan your product development
• Understand trends across technological and therapeutic fields to target resources effectively and recognize pipeline opportunities
• Optimize market penetration through improved knowledge of the growth drivers and corporate dynamics of the protein drug delivery market

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 200,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.